The ProPrems trial: Investigating the effects of probiotics on late onset sepsis in very preterm infants

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Garland, Suzanne M ^a,b,c   Tobin, Jacinta M ^b   Pirotta, Marie ^b   Tabrizi, Sepehr N ^a,b,c   Opie, Gillian ^d   Donath, Susan ^c   Tang, Mimi L K ^b,c   Morley, Colin J ^e   Hickey, Leah ^a,e   Ung, Linh ^a,e   Jacobs, Susan E ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d MERCY HOSPITAL FOR WOMEN   (Australia)

^e ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT; ANTIINFECTIVE AGENT; PLACEBO;

ARTICLE; ARTIFICIAL MILK; BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM INFANTIS; BLOOD CULTURE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENTERIC FEEDING; GESTATIONAL AGE; HUMAN; INFANT; INFANT MORTALITY; INFECTION PREVENTION; LACTOCOCCUS LACTIS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NECROTIZING ENTEROCOLITIS; NEWBORN MONITORING; NEWBORN SEPSIS; ONSET AGE; OUTCOME ASSESSMENT; PATIENT SAFETY; POSTNATAL GROWTH; PREMATURITY; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS THERMOPHILUS; VERY LOW BIRTH WEIGHT; AUSTRALIA; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET; DRUG UTILIZATION; FEMALE; INCIDENCE; MALE; METHODOLOGY; MORTALITY; NEW ZEALAND; NEWBORN; SEPSIS; STATISTICS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; AUSTRALIA; BODY WEIGHT; DIET; DOUBLE-BLIND METHOD; DRUG UTILIZATION; ENTEROCOLITIS, NECROTIZING; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LENGTH OF STAY; MALE; NEW ZEALAND; PLACEBOS; PREMATURE BIRTH; PROBIOTICS; SEPSIS; TREATMENT OUTCOME;

EID: 79961119221     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-210     Document Type: Article

References (75)

1. Abeywardana Australia New Zealand Neonatal Network Annual Report 2003. ANZNN Sydney 2005, Abeywardana.
2. Eckburg PB, et al. Diversity of the human intestinal microbial flora. Science 2005, 308(5728):1635-8. 10.1126/science.1110591, 1395357, 15831718.
3. Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 2002, 22:283-307. 10.1146/annurev.nutr.22.011602.092259, 12055347.
4. Turnbaugh PJ, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444(7122):1027-31. 10.1038/nature05414, 17183312.
5. Ley RE, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005, 102(31):11070-5. 10.1073/pnas.0504978102, 1176910, 16033867.
6. Manichanh C, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006, 55(2):205-11. 10.1136/gut.2005.073817, 1856500, 16188921.
7. Seksik P, et al. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther 2006, 24(Suppl 3):11-8.
8. Harmsen HJ, et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr 2000, 30(1):61-7. 10.1097/00005176-200001000-00019, 10630441.
9. Schwiertz A, et al. Development of the intestinal bacterial composition in hospitalized preterm infants in comparison with breast-fed, full-term infants. Pediatr Res 2003, 54(3):393-9. 10.1203/01.PDR.0000078274.74607.7A, 12788986.
10. Lubetzky R, et al. Mode of delivery and neonatal hematocrit. Am J Perinatol 2000, 17(3):163-5. 10.1055/s-2000-9291, 11012142.
11. Abeywardana Report of the Australian and New Zealand Neonatal Network 2006. ANZNN (Australian and New Zealand Neonatal Network) 2009 2009, ANZNN: Sydney, Abeywardana.
12. Wang Y, et al. 16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. ISME J 2009, 3(8):944-54. 10.1038/ismej.2009.37, 2713796, 19369970.
13. Mshvildadze M, et al. Intestinal microbial ecology in premature infants assessed with non-culture-based techniques. J Pediatr 2010, 156(1):20-5. 10.1016/j.jpeds.2009.06.063, 19783002.
14. Magne F, et al. Low species diversity and high interindividual variability in faeces of preterm infants as revealed by sequences of 16S rRNA genes and PCR-temporal temperature gradient gel electrophoresis profiles. FEMS Microbiol Ecol 2006, 57(1):128-38. 10.1111/j.1574-6941.2006.00097.x, 16819956.
15. Fanaro S, et al. Fecal flora measurements of breastfed infants using an integrated transport and culturing system. Acta Paediatr 2003, 92(5):634-5. 10.1111/j.1651-2227.2003.tb02521.x, 12839299.
16. Millar MR, et al. Application of 16S rRNA gene PCR to study bowel flora of preterm infants with and without necrotizing enterocolitis. J Clin Microbiol 1996, 34(10):2506-10. 229306, 8880510.
17. Sakata H, Yoshioka H, Fujita K. Development of the intestinal flora in very low birth weight infants compared to normal full-term newborns. Eur J Pediatr 1985, 144(2):186-90. 10.1007/BF00451911, 4043132.
18. Blakey JL, et al. Development of gut colonisation in pre-term neonates. J Med Microbiol 1982, 15(4):519-29. 10.1099/00222615-15-4-519, 6816935.
19. Gewolb IH, et al. Stool microflora in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1999, 80(3):F167-73. 10.1136/fn.80.3.F167, 1720923, 10212075.
20. (FAO)., F.a.A.O.o.t.U.N Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. 2001, (FAO)., F.a.A.O.o.t.U.N.
21. Orrhage K, Nord CE. Factors controlling the bacterial colonization of the intestine in breastfed infants. Acta Paediatr Suppl 1999, 88(430):47-57.
22. Duffy LC. Interactions mediating bacterial translocation in the immature intestine. J Nutr 2000, 130(2S Suppl):432S-436S.
23. Mattar AF, et al. Effect of probiotics on enterocyte bacterial translocation in vitro. Pediatr Surg Int 2001, 17(4):265-8. 10.1007/s003830100591, 11409159.
24. Link-Amster H, et al. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 1994, 10(1):55-63. 10.1111/j.1574-695X.1994.tb00011.x, 7874079.
25. Neu J, Caicedo R. Probiotics: protecting the intestinal ecosystem?. J Pediatr 2005, 147(2):143-6. 10.1016/j.jpeds.2005.05.033, 16126038.
26. Barclay AR, et al. Probiotics for necrotizing enterocolitis: a systematic review. J Pediatr Gastroenterol Nutr 2007, 45(5):569-76. 10.1097/MPG.0b013e3181344694, 18030235.
27. Guthmann F, Kluthe C, Buhrer C. Probiotics for prevention of necrotising enterocolitis: an updated meta-analysis. Klin Padiatr 2010, 222(5):284-90. 10.1055/s-0030-1254113, 20645240.
28. Deshpande G, et al. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010, 125(5):921-30. 10.1542/peds.2009-1301, 20403939.
29. Alfaleh K, et al. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011, 3:CD005496.
30. Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med 2011, 364(3):255-64. 10.1056/NEJMra1005408, 21247316.
31. Schimpl G, et al. Late intestinal strictures following successful treatment of necrotizing enterocolitis. Acta Paediatr Suppl 1994, 396:80-3.
32. Bisquera JA, Cooper TR, Berseth CL. Impact of necrotizing enterocolitis on length of stay and hospital charges in very low birth weight infants. Pediatrics 2002, 109(3):423-8. 10.1542/peds.109.3.423, 11875136.
33. Stoll BJ. Epidemiology of necrotizing enterocolitis. Clin Perinatol 1994, 21(2):205-18.
34. de la Cochetiere MF, et al. Early intestinal bacterial colonization and necrotizing enterocolitis in premature infants: the putative role of Clostridium. Pediatr Res 2004, 56(3):366-70. 10.1203/01.PDR.0000134251.45878.D5, 15201403.
35. Hoy C, et al. Quantitative changes in faecal microflora preceding necrotising enterocolitis in premature neonates. Arch Dis Child 1990, 65(10 Spec No):1057-9. 10.1136/adc.65.10_Spec_No.1057, 1590248, 2122814.
36. Stuart RL, et al. An outbreak of necrotizing enterocolitis associated with norovirus genotype GII.3. Pediatr Infect Dis J 2010, 29(7):644-7. 10.1097/INF.0b013e3181d824e1, 20589982.
37. Bell MJ, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978, 187(1):1-7. 10.1097/00000658-197801000-00001, 1396409, 413500.
38. Awad H, et al. Comparison between killed and living probiotic usage versus placebo for the prevention of necrotizing enterocolitis and sepsis in neonates. Pak J Biol Sci 2010, 13(6):253-62.
39. Mohan R, et al. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res 2008, 64(4):418-22. 10.1203/PDR.0b013e318181b7fa, 18552710.
40. Braga TD, et al. Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial. Am J Clin Nutr 2011, 93(1):81-6. 10.3945/ajcn.2010.29799, 20980486.
41. Fujii T, et al. Bifidobacterium breve enhances transforming growth factor beta1 signaling by regulating Smad7 expression in preterm infants. J Pediatr Gastroenterol Nutr 2006, 43(1):83-8. 10.1097/01.mpg.0000228100.04702.f8, 16819382.
42. Agarwal R, et al. Effects of oral Lactobacillus GG on enteric microflora in low-birth-weight neonates. J Pediatr Gastroenterol Nutr 2003, 36(3):397-402. 10.1097/00005176-200303000-00019, 12604982.
43. Cukrowska B, et al. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol 2002, 55(2):204-9. 10.1046/j.1365-3083.2002.01005.x, 11896937.
44. Garland SM, et al. A cautionary note on instituting probiotics into routine clinical care for premature infants. Pediatrics 2010, 126(3):e741-2. author reply e743-5, 10.1542/peds.2010-1949B, 20810714.
45. Soll RF. Probiotics: are we ready for routine use?. Pediatrics 2010, 125(5):1071-2. 10.1542/peds.2010-0643, 20421256.
46. Tarnow-Mordi WO, et al. Probiotics reduce all-cause mortality and necrotizing enterocolitis: it is time to change practice. Pediatrics 2010, 125(5):1068-70. 10.1542/peds.2009-2151, 20403934.
47. Dani C, et al. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 2002, 82(2):103-8. 10.1159/000063096, 12169832.
48. Lin HC, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005, 115(1):1-4.
49. Prescott SL, Tang ML. The Australasian Society of Clinical Immunology and Allergy position statement: Summary of allergy prevention in children. Med J Aust 2005, 182(9):464-7.
50. Penders J, et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut 2007, 56(5):661-7. 10.1136/gut.2006.100164, 1942165, 17047098.
51. Kalliomaki M, et al. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001, 107(1):129-34. 10.1067/mai.2001.111237, 11150002.
52. Bjorksten B, et al. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001, 108(4):516-20. 10.1067/mai.2001.118130, 11590374.
53. He F, et al. Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants. FEMS Immunol Med Microbiol 2001, 30(1):43-7. 10.1111/j.1574-695X.2001.tb01548.x, 11172990.
54. Ouwehand AC, et al. Differences in Bifidobacterium flora composition in allergic and healthy infants. J Allergy Clin Immunol 2001, 108(1):144-5.
55. Suzuki S, et al. Differences in the composition of intestinal Bifidobacterium species and the development of allergic diseases in infants in rural Japan. Clin Exp Allergy 2007, 37(4):506-11. 10.1111/j.1365-2222.2007.02676.x, 17430346.
56. Gore C, et al. Bifidobacterium pseudocatenulatum is associated with atopic eczema: a nested case-control study investigating the fecal microbiota of infants. J Allergy Clin Immunol 2008, 121(1):135-40. 10.1016/j.jaci.2007.07.061, 17900682.
57. Sjogren YM, et al. Altered early infant gut microbiota in children developing allergy up to 5 years of age. Clin Exp Allergy 2009, 39(4):518-26. 10.1111/j.1365-2222.2008.03156.x, 19220322.
58. Mohan R, et al. Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. J Clin Microbiol 2006, 44(11):4025-31. 10.1128/JCM.00767-06, 1698302, 16971641.
59. Hart AL, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004, 53(11):1602-9. 10.1136/gut.2003.037325, 1774301, 15479680.
60. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002, 109(1):119-21. 10.1067/mai.2002.120273, 11799376.
61. Pessi T, et al. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy 2000, 30(12):1804-8. 10.1046/j.1365-2222.2000.00948.x, 11122221.
62. Pohjavuori E, et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. J Allergy Clin Immunol 2004, 114(1):131-6. 10.1016/j.jaci.2004.03.036, 15241356.
63. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev 2007, (4):CD006475.
64. Tang ML, Lahtinen SJ, Boyle RJ. Probiotics and prebiotics: clinical effects in allergic disease. Curr Opin Pediatr 2010, 22(5):626-34.
65. Soh SE, et al. Probiotic supplementation in the first 6 months of life in at risk Asian infants--effects on eczema and atopic sensitization at the age of 1 year. Clin Exp Allergy 2009, 39(4):571-8. 10.1111/j.1365-2222.2008.03133.x, 19134020.
66. West CE, Hammarstrom ML, Hernell O. Probiotics during weaning reduce the incidence of eczema. Pediatr Allergy Immunol 2009, 20(5):430-7. 10.1111/j.1399-3038.2009.00745.x, 19298231.
67. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol 2007, 119(1):184-91. 10.1016/j.jaci.2006.08.036, 17208600.
68. Rautava S, Arvilommi H, Isolauri E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr Res 2006, 60(2):221-4. 10.1203/01.pdr.0000228317.72933.db, 16864708.
69. Williams HC, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994, 131(3):383-96. 10.1111/j.1365-2133.1994.tb08530.x, 7918015.
70. Boyle RJ, et al. Effects of Lactobacillus GG treatment during pregnancy on the development of fetal antigen-specific immune responses. Clin Exp Allergy 2008, 38(12):1882-90. 10.1111/j.1365-2222.2008.03100.x, 18823310.
71. Furet JP, Quenee P, Tailliez P. Molecular quantification of lactic acid bacteria in fermented milk products using real-time quantitative PCR. Int J Food Microbiol 2004, 97(2):197-207. 10.1016/j.ijfoodmicro.2004.04.020, 15541806.
72. Matsuki T, et al. Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-gene-targeted species-specific primers. Appl Environ Microbiol 1999, 65(10):4506-12. 91600, 10508082.
73. Haarman M, Knol J. Quantitative real-time PCR assays to identify and quantify fecal Bifidobacterium species in infants receiving a prebiotic infant formula. Appl Environ Microbiol 2005, 71(5):2318-24. 10.1128/AEM.71.5.2318-2324.2005, 1087546, 15870317.
74. Haarman M, Knol J. Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula. Appl Environ Microbiol 2006, 72(4):2359-65. 10.1128/AEM.72.4.2359-2365.2006, 1448991, 16597930.
75. Baert F, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138(2):463-8. quiz e10-1, 10.1053/j.gastro.2009.09.056, 19818785.